Active-ingredient Dossier
Insulin Glargine
Active-ingredient Dossier for Insulin Glargine (long acting insulin). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: OPTISULIN
- Brand: TOUJEO
- Brand: SEMGLEE
- Brand: BASAGLAR
- Brand: Lantus
- Therapeutic area: Endocrinology
What is
Insulin Glargine Insulin Glargine is a long acting insulin.
Australian brands containing
Insulin Glargine — OPTISULIN — TOUJEO — SEMGLEE — BASAGLAR
Therapeutic areas
Insulin Glargine is registered in endocrinology, with 5 brands containing the ingredient on the ARTG.
Sponsor landscape
Three sponsors market insulin glargine in Australia: Sanofi-Aventis, Eli Lilly and Maxx Pharma.
PBS and regulatory activity
Two brands containing insulin glargine have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2020–21 financial year, government expenditure on PBS-listed insulin glargine was $69,632,776.37 across 341,390 scripts. Four brands have PBAC outcomes on record, with the latest PBAC outcome dated 1 March 2019. One brand has an AusPAR on record, dated 10 November 2014.